The effects of slow loaded breathing training on exercise blood pressure in isolated systolic hypertension

2019 ◽  
Vol 24 (4) ◽  
Author(s):  
Chulee Ubolsakka‐Jones ◽  
Phailin Tongdee ◽  
David A. Jones
Keyword(s):  
Blood Pressure ◽  
Systolic Hypertension ◽  
Isolated Systolic Hypertension ◽  
Breathing Training ◽  
Exercise Blood Pressure ◽  
Loaded Breathing

The effect of slow-loaded breathing training on the blood pressure response to handgrip exercise in patients with isolated systolic hypertension

2017 ◽  
Vol 40 (10) ◽  
pp. 885-891 ◽  
Author(s):  
Chulee Ubolsakka-Jones ◽  
Benjarat Sangthong ◽  
Wilaiwan Khrisanapant ◽  
David A Jones
Keyword(s):  
Blood Pressure ◽  
Systolic Hypertension ◽  
Blood Pressure Response ◽  
Pressure Response ◽  
Handgrip Exercise ◽  
Isolated Systolic Hypertension ◽  
Breathing Training ◽  
Loaded Breathing

scholarly journals Isolated systolic hypertension and central blood pressure: Implications from the national nutrition and health survey in Taiwan

2020 ◽  
Author(s):  
Shao‐Yuan Chuang ◽  
Hsing‐Yi Chang ◽  
Tsung‐Ying Tsai ◽  
Hao‐Min Cheng ◽  
Wen‐Harn Pan ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Health Survey ◽  
Systolic Hypertension ◽  
Central Blood Pressure ◽  
Isolated Systolic Hypertension ◽  
Nutrition And Health

scholarly journals Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial

2001 ◽  
Vol 2 (1_suppl) ◽  
pp. S217-S222
Author(s):  
Matthew R Weir ◽  
Rebecca Y Wang
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Systolic Hypertension ◽  
Large Scale ◽  
Candesartan Cilexetil ◽  
Antihypertensive Drugs ◽  
Isolated Systolic Hypertension ◽  
Open Label ◽  
Background Therapy ◽  
Receptor Blockers

Angiotensin II (Ang II) receptor blockers are the newest class of antihypertensive drugs to be developed. No large-scale clinical trials have been performed to evaluate their efficacy alone, or in combination with other drugs. A large-scale, eight week, open-label, non-placebo-controlled, single-arm trial evaluated the efficacy, tolerability and dose-response of candesartan cilexetil, 16—32 mg once-daily, either as monotherapy or as part of combination therapy, in a diverse hypertensive population in actual practice settings. 6465 patients with high blood pressure, of whom 52% were female and 16% African American, with a mean age of 58 years, were included. 5446 patients had essential hypertension and 1014 patients had isolated systolic hypertension. In order to be included in this study, patients had either untreated or uncontrolled hypertension (systolic blood pressure (SBP) 140—179 mmHg and/or diastolic blood pressure (DBP) 90—109 mmHg inclusive at baseline), despite a variety of other antihypertensive drugs. Of the 5156 patients with essential hypertension and at least one post baseline efficacy measurement, the mean pretreatment blood pressure (BP) was 156/97 mmHg. Candesartan cilexetil monotherapy reduced mean SBP/DBP by 18.0/12.2 mmHg. Similarly, in the 964 patients with isolated systolic hypertension and at least one post baseline efficacy measurement, candesartan cilexetil monotherapy reduced SBP/DBP from 158/81 by 16.5/4.5 mmHg. Candesartan cilexetil was similarly effective when employed as add-on therapy. When added to baseline antihypertensive medication in 51% of the patients with essential hypertension not achieving BP control, additional reduction in BP was achieved regardless of the background therapy, including diuretics (17.8/11.7 mmHg) calcium antagonists (16.6/11.2 mmHg), beta-blockers (16.5/10.4 mmHg), angiotensin-converting enzyme inhibitors (ACE-I) (15.3/10.0 mmHg), and alpha blockers (16.4/10.4 mmHg). Likewise, when candesartan cilexetil was used as add-on therapy in patients with isolated systolic hypertension, there was a consistent further reduction of mean SBP/DBP, regardless of the background therapy. Moreover, these monotherapeutic or add-on efficacy benefits were seen regardless of age (<65 or >65 years), gender, or race. Despite the open-label design of the study which enhances efficacy owing to the placebo effect, the Ang II receptor blocker, candesartan cilexetil either alone, or as an add-on therapy, is highly effective for assisting in the control of systolic and diastolic hypertension.

Arterial hypertension + past stroke – a case report

2021 ◽  
Vol 14 (3) ◽  
pp. 324-326
Author(s):  
Maria Łukasiewicz ◽  
Marta Swarowska-Skuza
Keyword(s):  
Blood Pressure ◽  
Case Report ◽  
Chronic Disease ◽  
Side Effects ◽  
Arterial Hypertension ◽  
Antihypertensive Therapy ◽  
Systolic Hypertension ◽  
The Elderly ◽  
Isolated Systolic Hypertension ◽  
Special Group

Arterial hypertension, as a very widespread chronic disease, and thus differing in both pathomechanism and course in patients, requires a significant individualization of pharmacotherapy. One such special group is the elderly. Both the low-renin pathomechanism of arterial hypertension and its phenotype (isolated systolic hypertension) imply the choice of a specific pharmacotherapy. Additionally, in this group, side effects should be observed much more vigilantly, while target blood pressure values should be treated more liberally. An example of antihypertensive therapy in a patient belonging to the group described is presented in the following case.

EARLY MORNING SURGE BLOOD PRESSURE AND ISOLATED SYSTOLIC HYPERTENSION - A CLINICAL IMPORTANCE IN ELDERLY

2018 ◽  
Vol 36 (Supplement 1) ◽  
pp. e179
Author(s):  
M. Snincak ◽  
M. Zain El-Abdin ◽  
P. Hrabcakova ◽  
J. Pella ◽  
K. Kolesar
Keyword(s):  
Blood Pressure ◽  
Systolic Hypertension ◽  
Clinical Importance ◽  
Early Morning ◽  
Isolated Systolic Hypertension

PS 05-69 PREDICTORS OF HIGH AORTA BLOOD PRESSURE IN YOUNG MEN WITH ISOLATED SYSTOLIC HYPERTENSION

2016 ◽  
Vol 34 (Supplement 1) ◽  
pp. e159-e160
Author(s):  
Ganna Radchenko ◽  
Olena Torbas ◽  
Yuriy Sirenko ◽  
Olena Snitzarenko
Keyword(s):  
Blood Pressure ◽  
Systolic Hypertension ◽  
Young Men ◽  
Isolated Systolic Hypertension
Sign in / Sign up

Export Citation Format

Share Document